Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index; 17 of the 39 sources its claims cite were checked for support.

Overall and sex-specific effect of berberine for dyslipidemia: systematic review and meta-analysis of placebo-controlled trials

Open access

Preprint — published as 10.1007/s40265-023-01841-4 · Paper page

Abstract

Abstract Background Berberine is a nutraceutical that may improve lipid profiles. Berberine may also affect sex hormones and exert sex-specific effects, which has been overlooked. Objectives To comprehensively review the efficacy and safety of lipid-lowering effect of berberine with consideration of potential sex disparity. Methods Eligible studies were randomized controlled trials in adults that compared berberine versus placebo and measured blood lipids or lipoproteins. Studies were identified from Medline, Embase, Wanfang, CNKI, two clinical trial registries and previous systematic reviews. Mean differences (MD) were estimated using inverse variance weighting with random effects models. Risk of bias was assessed using the Cochrane risk of bias tool for randomized trials. Results 16 studies were included with treatment of 4 to 24 weeks. Berberine reduced low-density lipoprotein (LDL) cholesterol (−0.45 mmol/L, 95% CI -0.60 to -0.31, 12 studies, n=1,224), total cholesterol (−0.47 mmol/L, 95% CI -0.61 to -0.33, 15 studies, n=1,397), triglycerides (−0.32 mmol/L, 95% CI -0.44 to -0.19, 16 studies, n=1,421) and apolipoprotein B (−0.25 mg/dL, 95% CI -0.40 to -0.11, 2 studies, n=127). Berberine increased high-density lipoprotein (HDL) cholesterol by 0.06 mmol/L (95% CI 0.00 to 0.12, 13 studies, n=1,248). Notably, the effect on HDL cholesterol was different in women (0.11 mmol/L, 95% CI 0.09 to 0.13) from that in men (−0.07 mmol/L, 95% CI -0.16 to 0.02). Gastrointestinal adverse events were the most frequently reported adverse events. Conclusions Berberine decreased LDL cholesterol, triglycerides, and apolipoprotein B, with a potential sex-specific effect on HDL cholesterol. Large-scale trials considering sex disparity are required.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of 16 placebo-controlled randomized trials found that oral purified berberine improves lipid profiles in adults, lowering LDL cholesterol, total cholesterol, triglycerides, and apolipoprotein B while modestly raising HDL cholesterol. The effect on HDL cholesterol appeared sex-specific, favoring women over men, though the authors call for larger trials to confirm this.

Key findings

  • Berberine reduced LDL cholesterol by −0.45 mmol/L (95% CI −0.60 to −0.31; 12 studies, n=1,224), total cholesterol by −0.47 mmol/L (95% CI −0.61 to −0.33; 15 studies, n=1,397), triglycerides by −0.32 mmol/L (95% CI −0.44 to −0.19; 16 studies, n=1,421), and apolipoprotein B by −0.25 mmol/L (95% CI −0.40 to −0.11; 2 studies, n=127).
  • Berberine increased HDL cholesterol by 0.06 mmol/L (95% CI 0.00 to 0.12; 13 studies, n=1,248), with a sex-specific difference: women 0.11 mmol/L (95% CI 0.09 to 0.13) versus men −0.07 mmol/L (95% CI −0.16 to 0.02; P<0.01).
  • Trim-and-fill adjustment for publication bias attenuated effects to −0.23 mmol/L (95% CI −0.42 to −0.05) for total cholesterol and −0.20 mmol/L (95% CI −0.37 to −0.03) for triglycerides.
  • Gastrointestinal adverse events (constipation, diarrhea, nausea) appeared more frequent with berberine; no serious adverse events or muscle pain were reported in berberine groups. Withdrawal/discontinuation due to adverse events ranged from 2% to 6% of allocated patients in four studies.

Methods

  • Study-level systematic review and meta-analysis (PROSPERO CRD42021293218) of randomized controlled trials comparing purified berberine with placebo in adults ≥18 years, excluding plant extracts, combination products, and non-placebo comparators.
  • Searched MEDLINE, Embase, Wanfang, CNKI, ClinicalTrials.gov, and WHO ICTRP through December 2021, plus reference lists of prior reviews; 16 studies met eligibility (1,529 participants: 761 berberine, 768 placebo), with treatment durations of 4 to 24 weeks.
  • Mean differences with 95% CIs pooled using inverse-variance random-effects models (R package meta); heterogeneity assessed with I², publication bias with funnel plots and Egger's test, and subgroup analyses by sex, trial duration, dose, and ethnicity; risk of bias via Cochrane RoB 2 and certainty via GRADE.

Limitations

  • As stated by the authors: all eligible trials assessed surrogate lipid outcomes rather than cardiovascular events; follow-up was short (4–24 weeks), so long-term efficacy and safety remain unassessed; outcome reporting was potentially biased, with inconsistent reporting of lipid components and adverse events; and heterogeneity among pooled studies was high, addressed only through study-level subgroup analyses.
  • Evident from the text: the sex-specific HDL finding rests on a small number of single-sex studies (one all-male study, four in women with PCOS), and the authors themselves note the possibility that greater statistical power in women rather than a true biological difference may explain the result; apoB analyses included only 2 studies (n=127).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1101/2022.06.20.22276676

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow chart of study inclusion in the systematic review and meta-analysis
Figure 1 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flow chart of study inclusion in the systematic review and meta-analysisFrom the PDF
Image 2
From the PDF
Image 3
From the PDF
Image 4
From the PDF
Image 5
From the PDF
Image 6
From the PDF
Image 7
From the PDF

Verification

Claims the paper makes

12 Valid · 0 Not valid · 9 Not checked · 56 Own results and interpretations

21 more claims

Create a free account to see all 77 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 24
  • It may state two separate claims as one. 33

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 33 references

Research works printed but not linked: 7

  1. Blais J , Zhao JV , Huang X. Effect of berberine compared to placebo on lipid profiles: systematic review and meta-analysis of randomized controlled trials. PROSPERO; 2021. p. CRD42021293218.
  2. Li M , Li J , Liu Y , Zhao Y , Qiu Y , Jia Q , et al. The influence of berberine hydrochloride on glucolipid metabolism of patients with schizophrenia (Chinese). Chinese Journal of Prevention and Control of Chronic Diseases. 2016.
  3. 2012, The Clinical Study of Berberine in Patients with Polycystic Ovarian Syndrome and Insulin Resistance (Chinese), Tianjin Medical Journal, 40, 3
  4. 2016, Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia (Chinese), Chinese Journal of Integrated Traditional and Western Medicine, 36, 681
  5. 2016, Effect of berberine on symptoms and glycolipid metabolism in schizophrenia patients treated with risperidone (Chinese), Journal of Tianjin Medical University, 22, 338
  6. 2016, Effects of berberine combined with ethinylestradiol cyproterone acetate in the treatment of obese women with polycystic ovary syndrome (Chinese), Chinese Journal of Primary Medicine and Pharmacy, 23, 837
  7. 2021, Effect of berberine combined with metformin on body fat distribution and liver fat content in type 2 diabetic patients with NAFLD (Chinese), Zhejiang Medicine, 43, 2327

Metadata

Authors
Blais, J. E., Huang, X., & Zhao, J. V.
Affiliations
University of Hong Kong (HK)
Corresponding author
Zhao, Jie V
Venue
medRxiv
Publisher
openRxiv
Published
2022-06-21
Volume
83
Issue
5
Pages
403-427
ISSN
0012-6667 (ISSN-L)
OpenAlex
W4328048052
Cited by
31
References
33
Citations by year
2026: 12 · 2025: 13 · 2024: 4 · 2023: 2
FWCI
0.88
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Drugs (publishedVersion)
  • medRxiv (submittedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Natural Products and Biological Research
Keywords
berberine, dyslipidemia, hypolipidemic effect, sex differences, HDL cholesterol, LDL cholesterol, triglycerides, apolipoprotein B, total cholesterol, nutraceuticals, gastrointestinal adverse effects, drug safety, cardiovascular risk reduction, risk of bias assessment, quality of evidence grading, heterogeneity
MeSH terms
Adult, Apolipoproteins, Berberine, Cholesterol, Female, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Triglycerides, Randomized Controlled Trials as Topic, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overall and sex-specific effect of berberine for dyslipidemia: systematic review and meta-analysis of placebo-controlled trials. https://app.cochat.ai/papers/10.1101/2022.06.20.22276676
The paper
Blais, J. E., Huang, X., & Zhao, J. V. (2022). Overall and sex-specific effect of berberine for dyslipidemia: systematic review and meta-analysis of placebo-controlled trials. medRxiv. https://doi.org/10.1101/2022.06.20.22276676

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.